Department of Intensive Care Medicine, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Intensive Care Med. 2011 Dec;37(12):1951-61. doi: 10.1007/s00134-011-2376-0. Epub 2011 Nov 3.
Diaphragmatic electrical activity (EA(di)), reflecting respiratory drive, and its feedback control might be impaired in critical illness-associated polyneuromyopathy (CIPM). We aimed to evaluate whether titration and prolonged application of neurally adjusted ventilatory assist (NAVA), which delivers pressure (P (aw)) in proportion to EA(di), is feasible in CIPM patients.
Peripheral and phrenic nerve electrophysiology studies were performed in 15 patients with clinically suspected CIPM and in 14 healthy volunteers. In patients, an adequate NAVA level (NAVAal) was titrated daily and was implemented for a maximum of 72 h. Changes in tidal volume (V (t)) generation per unit of EA(di) (V (t)/EA(di)) were assessed daily during standardized tests of neuro-ventilatory efficiency (NVET).
In patients (median [range], 66 [44-80] years), peripheral electrophysiology studies confirmed CIPM. Phrenic nerve latency (PNL) was prolonged and diaphragm compound muscle action potential (CMAP) was reduced compared with healthy volunteers (p < 0.05 for both). NAVAal could be titrated in all but two patients. During implementation of NAVAal for 61 (37-64) h, the EA(di) amplitude was 9.0 (4.4-15.2) μV, and the V (t) was 6.5 (3.7-14.3) ml/kg predicted body weight. V (t), respiratory rate, EA(di), PaCO(2), and hemodynamic parameters remained unchanged, while PaO(2)/FiO(2) increased from 238 (121-337) to 282 (150-440) mmHg (p = 0.007) during NAVAal. V (t)/EA(di) changed by -10 (-46; +31)% during the first NVET and by -0.1 (-26; +77)% during the last NVET (p = 0.048).
In most patients with CIPM, EA(di) and its feedback control are sufficiently preserved to titrate and implement NAVA for up to 3 days. Whether monitoring neuro-ventilatory efficiency helps inform the weaning process warrants further evaluation.
膈肌电活动(EA(di))反映呼吸驱动力,其反馈控制在与危重病相关的多发性神经病(CIPM)中可能受损。我们旨在评估在 CIPM 患者中是否可以滴定和延长神经调节辅助通气(NAVA)的应用,NAVA 以 EA(di)的比例输送压力(P (aw))。
对 15 例临床疑似 CIPM 患者和 14 名健康志愿者进行了周围神经和膈神经电生理学研究。在患者中,每天滴定适当的 NAVA 水平(NAVAal),并最长应用 72 小时。在标准化神经通气效率(NVET)测试中,每天评估单位 EA(di)产生的潮气量(V (t))变化(V (t)/EA(di))。
在患者中(中位数[范围],66 [44-80] 岁),周围神经电生理学研究证实了 CIPM。与健康志愿者相比,膈神经潜伏期(PNL)延长,膈神经复合肌肉动作电位(CMAP)降低(均 p < 0.05)。除两名患者外,所有患者均能滴定 NAVAal。在应用 NAVAal 61(37-64)小时期间,EA(di) 幅度为 9.0(4.4-15.2)μV,潮气量为 6.5(3.7-14.3)ml/kg 预测体重。潮气量、呼吸频率、EA(di)、PaCO(2) 和血流动力学参数保持不变,而 PaO(2)/FiO(2) 在应用 NAVAal 期间从 238(121-337)增加至 282(150-440)mmHg(p = 0.007)。在第一次 NVET 期间,V (t)/EA(di) 变化-10(-46;+31)%,在最后一次 NVET 期间变化-0.1(-26;+77)%(p = 0.048)。
在大多数 CIPM 患者中,EA(di)及其反馈控制足以保留,以滴定和实施 NAVA 长达 3 天。监测神经通气效率是否有助于指导撤机过程仍有待进一步评估。